Septerna, Inc. SEPN 深 沪
等待开盘 05-22 09:30:00 美东时间
27.92
-0.090
-0.32%
华盛通- 最 高28.595
- 今 开27.62
- 成交量 23.24万股
- 最 低 27.49
- 昨 收 28.01
- 总市值 12.59亿
- 52周最高 32.63
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 9.2804
- 委 比 0.00%
- 总股本 4507.55万
- 历史最高 32.63
- 量 比 0.57
- 振 幅 3.95%
- 历史最低 4.17
- 每 手 1
- 风险率 6.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
PatentVest's report highlights the rapid expansion of triple-agonist programs in obesity therapeutics, with 27 global projects across major pharma companies and emerging biotechs. The study emphasizes the shift from clinical outcomes to intellectual property strategies, receptor engineering, and delivery systems as key factors shaping the next phase of competition. China is a significant player in this pipeline expansion. Companies like Eli Lilly...
05-08 14:30
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy and maintains $40 price target.
04-14 19:13
Septerna Initiates Phase 1 Clinical Trial Of SEP-479
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy VolunteersData Anticipated in Late 2026 or Early 2027
04-13 20:07
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
JP Morgan Maintains Overweight on Septerna, Raises Price Target to $38
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the price target from $34 to $38.
03-25 02:13
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Truist Securities Maintains Buy on Septerna, Raises Price Target to $35
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $34 to $35.
03-11 21:52
Septerna Files Shelf Registration For Future Offerings Of Stock, Debt, Warrants, And Units
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or more series or classes, our common stock, preferred stock, debt securities, warrants and/or units, in any combination,
03-11 04:34
